Erasca, Inc. entered into an underwriting agreement to sell 31,428,572 shares of common stock at $17.50 per share. The company expects net proceeds of approximately $516 million, or $593.5 million if underwriters exercise their option to purchase additional shares. The offering is expected to close on July 15, 2026.

View Full Filing (SEC EDGAR)

2026-07-13

Erasca, Inc. announced updated Phase 1 data for its experimental drug ERAS-0015, a pan-RAS molecular glue. In a seven-patient subgroup with a specific type of pancreatic cancer at the recommended dose, 57% had a confirmed or unconfirmed response within eight weeks. The company also reported no dose-limiting toxicities in a combination study with panitumumab for colorectal cancer. Erasca plans to start registration-enabling trials in non-small cell lung cancer and pivotal Phase 3 trials in pancreatic cancer in 2027.

View Full Filing (SEC EDGAR)

2026-07-01

Erasca, Inc. held its annual meeting on June 26, 2026. Shareholders voted to elect three Class II directors—Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.—each receiving over 219 million votes in favor. They also ratified KPMG LLP as the independent accounting firm for fiscal 2026 with about 264.6 million votes in favor, 1.4 million withheld, and 70,000 against.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding ERASCA INC (ERAS)?

Major stakeholders currently include Frazier Life Sciences Management, L.P. ($399.2M), T. Rowe Price Investment Management, Inc. ($344.0M), BlackRock, Inc. ($326.0M). Based on the latest 13F filings, there are a total of 227 tracked investment funds and institutions maintaining positions in ERAS.

What is the overall institutional sentiment toward ERAS recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $3.6B, driven by 170 managers accumulating shares while 65 reduced their exposure.

Which institutions have been selling or reducing their ERAS positions?

In the latest period, 40 funds trimmed their holdings, and 25 managers completely exited their positions. The aggregate reported sell value was $364.4M.

Are there any notable investors adding ERAS to their portfolios?

Yes, buying activity remains notable. 92 institutions opened new positions in {ticker}, and 78 existing holders added to their shares. The total reported buy value for the quarter amounted to $3.2B.